Evidence map›Paper›PMID 42396271›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Type 2 diabetes genetics in 125,000 admixed adults from Mexico City.

Jason M Torres, Jaime Berumen, Diego Aguilar-Ramirez, Eirini Trichia, Francisco Barajas-Olmos, Humberto García-Ortiz, Sam Morris, Michael Turner, Elizabeth Barrera, Tianshu Liu and 27 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Jason M TorresClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-7537-7035
Jaime BerumenUnidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0001-6707-3317
Diego Aguilar-RamirezClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-2298-3768
Eirini TrichiaClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-7655-5905
Francisco Barajas-OlmosClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0001-5064-6203
Humberto García-OrtizLaboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.ORCID 0000-0002-0453-980X
Sam MorrisClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-4067-1100
Michael TurnerClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-0351-4053
Elizabeth BarreraUnidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0009-0005-6168-8173
Tianshu LiuClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Consuelo D Quinto-CortésAging Research Center, Cinvestav Sede Sur, Center for Research and Advanced Studies of the National Polytechnic Institute, Mexico City, Mexico.ORCID 0000-0002-0338-3321
Lauren E PettyVanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-1619-6303
Lourdes García-GarcíaInstituto Nacional de Salud Pública, Cuernavaca, Mexico.ORCID 0000-0001-5262-1157
María Teresa Tusié-LunaUnidad de Biología Molecular y Medicina Genómica, Instituto de Investigaciones Biomédicas UNAM/Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Carlos A Aguilar-SalinasInstituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán" / Escuela de Medicina, Tecnológico de Monterrey, Mexico City, Mexico.
Amanda Y ChongCentre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Paulina BacaUnidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0002-0617-5931
Fernando RivasUnidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Fiona BraggClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-9181-6886
Louisa Gnatiuc FriedrichsClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0002-0641-2220
Michael R HillClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Lisa HollandClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-1799-4307
Alejandra Vergara-LopeClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0001-6262-2233
Rachel WadeClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Michael J GazianoDepartment of Aging, Brigham and Women's Hospital, Boston, MA 02215, USA.
Rory CollinsClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Eleanor WheelerCentre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID 0000-0002-8616-6444
Alan R ShuldinerRegeneron Genetics Center, Tarrytown, NY, USA.ORCID 0000-0001-9921-4305
Jennifer E BelowVanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Kari E NorthDepartment of Epidemiology, The University of Texas Health Science Center at Houston School of Public Health, Brownsville, TX, USA.ORCID 0000-0002-8903-0366
Alexandre C PereiraDepartment of Aging, Brigham and Women's Hospital, Boston, MA 02215, USA.
Andrés Moreno-EstradaAging Research Center, Cinvestav Sede Sur, Center for Research and Advanced Studies of the National Polytechnic Institute, Mexico City, Mexico.ORCID 0000-0001-8329-8292
Lorena OrozcoLaboratorio de Inmunogenómica y Enfermedades Metabólicas, Instituto Nacional de Medicina Genómica, Tlalpan, Mexico City, Mexico.ORCID 0000-0002-5801-9180
Jesús Alegre-DíazUnidad de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0001-9390-3871
Pablo Kuri-MoralesTecnológico de Monterrey, Proyecto OriGen, Monterrey, Mexico.
Jonathan R EmbersonClinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0001-7792-9422
Roberto Tapia-ConyerFaculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.

Funding

Hispanic Latino Lipid ConsortiumR01HL142302 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jennifer Below, JOSEPH MCCORMICK · 2018 to 2026
$5.8M
NHLBI NIH HHS R01 HL142302Wellcome Trust
6 · The paper itself

Abstract

Type 2 diabetes (T2D) is a highly heritable, polygenic disease with over 600 loci identified through genome-wide association studies (GWAS). However, despite possessing unique genetic variation shaped by demographic history and admixture, Latin American populations remain markedly underrepresented in global genomic research. To address this gap, we conducted genome- and exome-wide analyses of 19,431 T2D cases and 105,611 controls from the Mexico City Prospective Study (MCPS). We identified 86 independent GWAS associations, including 21 novel signals, 15 of which replicated in external cohorts. Risk alleles at novel loci were enriched in individuals with Indigenous American ancestry. Exome analyses revealed rare and ultra-rare missense variants with substantial risk effects at

Identifiers

PMID42396271
PMCPMC13320931

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.